Investor FAQs
Show All
Where are UroGen Pharma’s corporate headquarters?
UroGen is headquartered in Princeton, NJ with operations in Israel.
When was UroGen Pharma founded?
UroGen Pharma was founded in 2004.
Who are the members of UroGen Pharma's Board of Directors?
You can view our Board of Directors by visiting the Board of Directors section on our website.
Who are the members of UroGen Pharma's Management Team?
You can view our Management Team by visiting the Management section on our website.
Who are the members of UroGen Scientific Advisory Board?
You can view our Scientific Advisory Board members by visiting the Scientific Advisory Board section on our website.
On which exchange is UroGen Pharma listed and what is the ticker symbol?
UroGen is traded on the NASDAQ Global Market under the symbol “URGN.”
Who is UroGen Pharma's independent registered public accounting firm?
UroGen Pharma’s independent registered public accounting firm is PriceWaterhouseCoopers Israel.

PriceWaterhouseCoopers Israel
PO Box 50005
Tel-Aviv 6150001
Telephone: [972] (0) 3 795 4555
When is UroGen Pharma’s fiscal year end?
UroGen Pharma’s fiscal year end is December 31.
When did UroGen Pharma go public?
UroGen Pharma went public on May 4, 2017.
How can I obtain UroGen Pharma’s investor relations materials?
You can obtain UroGen Pharma’s investor relations material in the Investors section of our website.
How can I purchase shares?
Shares can be purchased through a stockbroker of your choice.
Does UroGen Pharma have a direct stock purchase plan?
UroGen Pharma does not offer a direct stock purchase plan.
Does UroGen Pharma pay dividends and have a dividend reinvestment program?
Currently, UroGen Pharma does not pay dividend or offer a dividend reinvestment program.
Who is UroGen Pharma’s transfer agent and how do I contact them?

UroGen Pharma’s transfer agent is Computershare Information. Please see below for the transfer agent contact information.

Written requests
By regular mail:
PO Box 505000
Louisville KY 40233-5000

By overnight delivery:
462 South 4th Street, Suite 1600
Louisville KY 40202

How can I get a copy of your Annual Report or any other Investor materials (i.e., Investor Relations kit, 10-k)?
Quarterly & Annual Reports and other investor materials are available under the SEC Filings page of the Investors section of the corporate website. Additionally, all SEC filings can also be accessed directly from the SEC website.
Where can I find recent UroGen Pharma press releases?
You can view our recent press releases by visiting the Press Releases section of our website.
Who can I contact if I am a member of the media?
Steve Klass at Burns McClellan at +1-212-213-0006 or
Where can I find more information on UroGen Pharma’s R&D programs?
You can view UroGen Pharma’s R&D plans by visiting the Pipeline section of our website.
How can I sign up to receive UroGen Pharma’s press releases and other company information?
Please visit the News section of our corporate website and choose the Email Alerts to be added to UroGen Pharma’s distribution list.
If I have questions regarding UroGen Pharma that have not been answered, whom should I contact?
For investor relations inquiries, you may submit inquiries by contacting Steve Klass at Burns McClellan at +1-212-213-0006 or

Information Request

Material Selections

Primary IR Contact

Sara Blum Sherman
Head of Investor Relations
Phone: 609-467-4975